Flag of the European Union EU Clinical Trials Register Help

Clinical trials for boehringer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    904 result(s) found for: boehringer. Displaying page 14 of 46.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next» Last»»
    EudraCT Number: 2008-005615-18 Sponsor Protocol Number: 1200.32 Start Date*: 2009-09-28
    Sponsor Name:Boehringer Ingelheim
    Full Title: LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activ...
    Medical condition: Adenocarcinoma of the lung
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001164 Adenocarcinoma lung stage III LLT
    9.1 10001165 Adenocarcinoma lung stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) GB (Completed) BE (Completed) AT (Completed) DE (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004803-36 Sponsor Protocol Number: 1199.13 Start Date*: 2009-03-30
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy i...
    Medical condition: stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10066490 Progression of non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) AT (Completed) DK (Completed) LT (Completed) ES (Completed) SK (Completed) GB (Completed) FR (Completed) PT (Completed) BG (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001291-38 Sponsor Protocol Number: 1230.27 Start Date*: 2013-09-23
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co.KG
    Full Title: Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability and toxicity of volasertib in paediatric patients from 2 years to less than 18 y...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10048683 Advanced cancer LLT
    17.1 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) CZ (Completed) AT (Completed) SK (Completed) BE (Completed) NL (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003101-17 Sponsor Protocol Number: 1293-0013 Start Date*: 2017-12-07
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment ...
    Medical condition: lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) DE (Completed) PT (Completed) PL (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024251-87 Sponsor Protocol Number: 1199.32 Start Date*: 2011-04-12
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pul...
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed) IE (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002634-41 Sponsor Protocol Number: 1297.3 Start Date*: 2016-01-07
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Long-term assessment of safety, efficacy, pharmacokinetics and immunogenicity of BI 695501 in patients with rheumatoid arthritis (RA): an open-label extension trial for patients who have completed ...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) DE (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-002908-33 Sponsor Protocol Number: 1301.2 Start Date*: 2013-01-22
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated ...
    Medical condition: Untreated stage III or IV non-Hodgkin’s lymphoma (CD20+ Follicular Lymphoma of Grade 1, 2 or 3a, requiring chemotherapy)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) CZ (Prematurely Ended) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-016251-21 Sponsor Protocol Number: 205.458 Start Date*: 2010-10-29
    Sponsor Name:Boehringer Ingelheim
    Full Title: Pharmacokinetics and dose-ranging of tiotropium inhalation solution delivered from the Respimat inhaler in patients with Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002945-40 Sponsor Protocol Number: 1297.2 Start Date*: 2014-09-22
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) EE (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002671-18 Sponsor Protocol Number: 1237.16 Start Date*: 2014-04-02
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixe...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) BE (Completed) PT (Completed) DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001814-33 Sponsor Protocol Number: 1200.123 Start Date*: 2011-12-29
    Sponsor Name:Boehringer Ingelheim
    Full Title: LUX-Lung 7: A randomised, open-label Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung
    Medical condition: Recurrent, advanced or metastatic non-small cell lung cancer harbouring activating EGFR mutations with adnocarcinomatous histology
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025048 Lung cancer non-small cell recurrent LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) NO (Completed) GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003744-84 Sponsor Protocol Number: 1346-0012 Start Date*: 2021-05-31
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophren...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) NL (Completed) FR (Completed) SK (Completed) ES (Completed) HR (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002166-38 Sponsor Protocol Number: 205.301 Start Date*: 2005-01-19
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A 12-week randomized, double blind, placebo controlled, parallel group trial evaluating the efficacy and safety of inhaled Tiotropium 18µg q.d. in patients with COPD and a concomitant diagnosis of ...
    Medical condition: Patients with COPD (chronic obstructive pulmonary disease) and a concomitant diagnosis of asthma (asthma bronchiale).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010952 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003535-27 Sponsor Protocol Number: 1241.36 Start Date*: 2012-10-17
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended p...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) GB (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002536-94 Sponsor Protocol Number: 1160.47 Start Date*: 2006-03-20
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2...
    Medical condition: Confirmed Venous Thromboembolism (VTE) i.e. uni or bilateral deep vein thrombosis (DVT) of the leg involving proximal veins and/or pulmonay embolism (PE) - treated with anticoagulant for 3 to 6 mo...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) SE (Completed) CZ (Completed) BE (Completed) SK (Completed) GB (Completed) ES (Completed) DE (Completed) HU (Completed) PT (Completed) GR (Completed) DK (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-004528-35 Sponsor Protocol Number: 1239.6 Start Date*: 2007-01-22
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2...
    Medical condition: Metastatic colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-002390-60 Sponsor Protocol Number: 1404-0002 Start Date*: 2020-04-23
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: A Phase II, randomized, parallel group, dose-finding study of subcutaneously administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes m...
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) HU (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002930-33 Sponsor Protocol Number: 1366-0022 Start Date*: 2021-09-02
    Sponsor Name:Boehringer Ingelheim Pharma GmbH&Co.
    Full Title: Randomised, double-blind (within dose groups), placebo-controlled and parallel group trial to investigate the effects of different doses of oral BI 685509 given over 20 weeks on UACR reduction in p...
    Medical condition: non-diabetic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) PT (Completed) DE (Completed) PL (Completed) ES (Restarted)
    Trial results: View results
    EudraCT Number: 2016-001642-26 Sponsor Protocol Number: LRD.2016.STREAM2 Start Date*: 2017-10-02
    Sponsor Name:Leuven Research & Development (LRD) at University of Leuven, Belgium
    Full Title: STREAM-2 (STrategic Reperfusion in elderly patients Early After Myocardial Infarction)
    Medical condition: ST-elevation myocardial infarction within 3 hours of onset of symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000011652 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-002276-16 Sponsor Protocol Number: 1218.60 Start Date*: 2011-11-15
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised, double-blind, double-dummy active-comparator controlled study investigating the efficacy and safety of Linagliptin co-administered with metformin QD at evening time versus metformin B...
    Medical condition: Type 2 diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Aug 07 10:44:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA